Hongwei Gao Selected Research

CCAAT-Enhancer-Binding Proteins

1/2017	2-Methoxyestradiol protects against IgG immune complex-induced acute lung injury by blocking NF-κB and CCAAT/enhancer-binding protein β activities.
1/2016	Bigelovii A Protects against Lipopolysaccharide-Induced Acute Lung Injury by Blocking NF-κB and CCAAT/Enhancer-Binding Protein δ Pathways.
8/2013	Myeloid depletion of SOCS3 enhances LPS-induced acute lung injury through CCAAT/enhancer binding protein δ pathway.
2/2013	CCAAT/enhancer-binding protein δ is a critical mediator of lipopolysaccharide-induced acute lung injury.
8/2012	Critical role for CCAAT/enhancer-binding protein β in immune complex-induced acute lung injury.
1/2012	C5a-regulated CCAAT/enhancer-binding proteins β and δ are essential in Fcγ receptor-mediated inflammatory cytokine and chemokine production in macrophages.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hongwei Gao Research Topics

Disease

24	Inflammation (Inflammations) 02/2022 - 07/2006
23	Neoplasms (Cancer) 04/2022 - 10/2013
16	Acute Lung Injury 01/2022 - 03/2005
16	Sepsis (Septicemia) 10/2018 - 08/2003
11	Infections 01/2022 - 10/2010
9	Lung Injury 01/2022 - 03/2005
8	Pneumonia (Pneumonitis) 01/2022 - 04/2005
7	Lung Neoplasms (Lung Cancer) 02/2022 - 01/2015
7	Neoplasm Metastasis (Metastasis) 02/2022 - 10/2013
6	Necrosis 01/2022 - 06/2012
5	Alzheimer Disease (Alzheimer's Disease) 01/2021 - 12/2017
5	Acute Kidney Injury (Acute Renal Failure) 01/2021 - 01/2017
4	Edema (Dropsy) 08/2021 - 11/2009
3	COVID-19 01/2022 - 03/2021
3	Osteosarcoma (Osteogenic Sarcoma) 01/2019 - 12/2014
3	Hemorrhage 01/2019 - 11/2009
3	Bacterial Infections (Bacterial Infection) 11/2013 - 01/2009
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 01/2021
2	Femoral Neck Fractures 02/2020 - 06/2012
2	Body Weight (Weight, Body) 10/2019 - 07/2013
2	Type 2 Diabetes Mellitus (MODY) 08/2019 - 01/2018
2	Gastroesophageal Reflux (GERD) 05/2019 - 07/2018
2	Hepatocellular Carcinoma (Hepatoma) 01/2019 - 11/2016
2	Bone Resorption 01/2019 - 01/2013
2	Pain (Aches) 06/2018 - 06/2012
2	Breast Neoplasms (Breast Cancer) 11/2017 - 03/2016
2	Colorectal Neoplasms (Colorectal Cancer) 09/2017 - 10/2013
2	Wounds and Injuries (Trauma) 01/2015 - 05/2009
2	Bacteremia 07/2008 - 07/2005
1	Hypertension (High Blood Pressure) 04/2022
1	Spinal Cord Injuries (Spinal Cord Injury) 01/2022
1	Lewis Lung Carcinoma 01/2022

Drug/Important Bio-Agent (IBA)

16	Proteins (Proteins, Gene)FDA Link 01/2022 - 03/2005
14	CytokinesIBA 01/2022 - 07/2005
11	Immunoglobulin G (IgG)IBA 01/2017 - 03/2005
9	Pharmaceutical PreparationsIBA 04/2022 - 07/2010
9	Antigen-Antibody Complex (Immune Complex)IBA 01/2017 - 03/2005
6	LipopolysaccharidesIBA 01/2022 - 04/2005
6	CCAAT-Enhancer-Binding ProteinsIBA 01/2017 - 01/2012
5	Biological ProductsIBA 04/2022 - 03/2016
5	Therapeutic UsesIBA 01/2022 - 10/2019
5	MicroRNAs (MicroRNA)IBA 03/2019 - 10/2010
4	Hematoxylin (Haematoxylon)IBA 01/2022 - 01/2020
4	Eosine Yellowish-(YS) (Eosin)IBA 01/2022 - 01/2020
4	Xylenes (Xylene)IBA 08/2021 - 01/2017
4	Biomarkers (Surrogate Marker)IBA 01/2021 - 10/2013
4	Phosphotransferases (Kinase)IBA 01/2020 - 11/2013
4	EnzymesIBA 01/2020 - 10/2007
4	Interleukin-6 (Interleukin 6)IBA 01/2020 - 02/2004
4	LipidsIBA 10/2018 - 11/2013
4	ChemokinesIBA 06/2018 - 12/2004
4	NF-kappa B (NF-kB)IBA 11/2017 - 08/2003
4	Complement System Proteins (Complement)IBA 01/2012 - 01/2006
3	InflammasomesIBA 01/2022 - 01/2020
3	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2022 - 01/2015
3	AcidsIBA 08/2020 - 07/2018
3	2-methoxy-6-acetyl-7-methyljugloneIBA 10/2019 - 03/2016
3	Small Interfering RNA (siRNA)IBA 01/2019 - 11/2013
3	AntibodiesIBA 12/2017 - 06/2005
3	Messenger RNA (mRNA)IBA 12/2016 - 12/2004
3	Anaphylatoxin C5a ReceptorIBA 01/2012 - 02/2004
2	cucurbitacin BIBA 02/2022 - 01/2021
2	Protein Kinases (Protein Kinase)IBA 01/2022 - 01/2020
2	theasinensin AIBA 01/2020 - 01/2019
2	Ceftriaxone (Ceftriaxon)FDA LinkGeneric 01/2020 - 01/2015
2	Peroxidase (Myeloperoxidase)IBA 01/2020 - 03/2005
2	anemoside B4IBA 01/2020 - 01/2020
2	CalciumIBA 10/2019 - 01/2017
2	Dipeptidyl-Peptidase IV InhibitorsIBA 08/2019 - 01/2018
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 04/2019 - 10/2016
2	Caspase 3 (Caspase-3)IBA 01/2019 - 01/2018
2	Long Noncoding RNAIBA 01/2019 - 08/2018
2	resolvin D1IBA 10/2018 - 10/2014
2	AlbuminsIBA 10/2018 - 03/2005
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2018 - 03/2016
2	liriodendrinIBA 11/2017 - 10/2016
2	CaspasesIBA 01/2017 - 03/2016
2	RicinIBA 06/2012 - 05/2009
2	Transcription Factors (Transcription Factor)IBA 12/2011 - 01/2006
1	Doxorubicin (Adriamycin)FDA LinkGeneric 04/2022
1	Antineoplastic Agents (Antineoplastics)IBA 04/2022
1	Epidermal Growth Factor (EGF)IBA 02/2022
1	CurcuminIBA 01/2022
1	Cisplatin (Platino)FDA LinkGeneric 01/2022
1	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2022
1	Medical Waste (Waste, Medical)IBA 01/2022
1	ChitosanIBA 01/2022
1	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2022
1	2- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA 01/2022
1	NLR ProteinsIBA 01/2022
1	RNA (Ribonucleic Acid)IBA 01/2022

Therapy/Procedure

9	Ligation 10/2018 - 02/2004
9	Punctures 10/2018 - 02/2004
4	Chinese Traditional Medicine (Traditional Chinese Medicine) 02/2021 - 11/2017
2	Aftercare (After-Treatment) 02/2022 - 02/2020
2	Intraperitoneal Injections 01/2022 - 10/2019
2	Therapeutics 08/2018 - 04/2012
2	Drug Therapy (Chemotherapy) 07/2018 - 07/2010
1	Intravenous Injections 02/2022
1	Stem Cell Transplantation 01/2022